Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

We have observed 12 EP applications Hans-Peter Hauser has served for within the last five+ years. (We consider all applications which have an EP A1 or A2 publication dated after June 26, 2013). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP12777895

USE OF SULFATED GLYCOSAMINOGLYCANS FOR IMPROVING THE BIOAVAILABILITY OF FACTOR VIII

IPC classification:
A61K 47/42, A61K 47/36, A61K 38/37, A61K 38/36, A61P 7/04
Applicant:
CSL Behring GmbH
Agent:
Hans-Peter Hauser, CSL Behring GmbH
Status:
PATENT GRANTED
EP12772969

COMBINED USE OF A SULFATED GLYCOSAMINOGLYCAN AND A HYALURONIDASE FOR IMPROVING THE BIOAVAILABILITY OF FACTOR VIII

IPC classification:
A61K 47/42, A61K 47/36, A61K 38/37, A61K 38/36, A61P 7/04
Applicant:
CSL Behring GmbH
Agent:
Hans-Peter Hauser, CSL Behring GmbH
Status:
PATENT GRANTED
EP12772987

METHOD FOR IMPROVING THE STABILITY OF PURIFIED FACTOR VIII AFTER RECONSTITUTION

IPC classification:
A61K 38/37, C07K 14/755
Applicant:
CSL Ltd.
Agent:
Hans-Peter Hauser, CSL Behring GmbH
Status:
EXAMINATION IN PROGRESS
EP12859136

DOSAGE REGIME FOR APOLIPOPROTEIN FORMULATIONS

IPC classification:
A61K 38/17, A61K 35/14, A61P 9/00
Applicant:
CSL Ltd.
Agent:
Hans-Peter Hauser, CSL Behring GmbH
Status:
GRANT OF PATENT INTENDED
EP14192277

Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life

IPC classification:
A61K 38/37, G01N 33/86, C12N 15/12, C12N 5/10, C07K 14/755
Applicant:
CSL Behring GmbH
Agent:
Hans-Peter Hauser, CSL Behring GmbH
Status:
The patent has been granted
EP15193455

METHOD FOR PURIFICATION OF ALPHA-1-ANTITRYPSIN

IPC classification:
C07K 14/81
Applicant:
CSL Behring LLC
Agent:
Hans-Peter Hauser, CSL Behring GmbH
Status:
EXAMINATION REQUESTED
EP14859399

NEW METHOD TO CONCENTRATE VON WILLEBRAND FACTOR OR COMPLEXES THEREOF

IPC classification:
B01D 17/00, C07K 14/745
Applicant:
CSL Ltd.
Agent:
Hans-Peter Hauser, CSL Behring GmbH
Status:
EXAMINATION REQUESTED
EP14874688

FUSION PROTEINS COMPRISING FACTOR IX FOR PROPHYLACTIC TREATMENT OF HEMOPHILIA AND METHODS THEREOF

IPC classification:
C12N 15/09, C12N 9/64, C07K 19/00, C07K 14/765, C07K 14/745, A61P 7/04, A61K 38/38, A61K 38/36
Applicant:
CSL Ltd.
Agent:
Hans-Peter Hauser, CSL Behring GmbH
Status:
EXAMINATION REQUESTED
EP15775929

HALF-LIFE EXTENDED FACTOR FVIIA PROTEIN FOR PREVENTION AND TREATMENT OF BLEEDING AND DOSING REGIMENS THEREFOR

IPC classification:
A61P 7/04, A61K 38/36, C07K 14/745, C07K 19/00
Applicant:
CSL Ltd.
Agent:
Hans-Peter Hauser, CSL Behring GmbH
Status:
EXAMINATION REQUESTED
EP15741220

FACTOR VIII FORMULATION

IPC classification:
A61K 9/19, A61K 38/37
Applicant:
CSL Ltd.
Agent:
Hans-Peter Hauser, CSL Behring GmbH
Status:
EXAMINATION REQUESTED
EP15741222

IMPROVED FACTOR VIII PREPARATIONS SUITABLE FOR THERAPEUTIC USE AND PROCESSES TO OBTAIN THESE

IPC classification:
A61P 7/04, A61K 38/37
Applicant:
CSL Behring GmbH
Agent:
Hans-Peter Hauser, CSL Behring GmbH
Status:
Request for examination was made
EP16203579

A RECONSTITUTED HIGH DENSITY LIPOPROTEIN FORMULATION AND PRODUCTION METHOD THEREOF

IPC classification:
A61K 9/127, A61K 38/17, A61K 45/06, A61P 9/10, A61P 3/06, A61K 31/685, A61K 31/56
Applicant:
CSL Ltd.
Agent:
Hans-Peter Hauser, CSL Behring GmbH
Status:
Request for examination was made

Please Sign in to use this feature